RoActemra®

Known as: RoActemra 
 

Topic mentions per year

Topic mentions per year

2009-2018
012320092018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
K-Ras mutations are a hallmark of human pancreatic adenocarcinoma (PDAC) and epithelial-mesenchymal-transition (EMT) is a driver… (More)
Is this relevant?
2014
2014
Therapeutic monoclonal immunoglobulins (biologic drugs) are increasingly used in the treatment of conditions, such as autoimmune… (More)
  • table 1
Is this relevant?
Review
2013
Review
2013
Tocilizumab (Actemra®, RoActemra®) is a humanized monoclonal antibody that acts as an interleukin-6 receptor antagonist… (More)
  • table 1
  • table 3
  • table 4
  • figure 1
  • table 5
Is this relevant?
2011
2011
Tocilizumab (TCZ; RoActemra® or Actemra®) is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6… (More)
  • table 1
  • table 2
  • figure 1
  • table 8
  • table 7
Is this relevant?
Review
2010
Review
2010
  • Drug and therapeutics bulletin
  • 2010
Tocilizumab (RoActemra-Roche) is a new biological agent available in the UK for the treatment of adults with rheumatoid arthritis… (More)
Is this relevant?
Review
2009
Review
2009
Tocilizumab (RoActemra or Actemra) is a recombinant humanized monoclonal antibody that acts as an interleukin (IL)-6 receptor… (More)
  • table I
  • table II
  • table III
  • table III
  • figure 1
Is this relevant?
2009
2009
Der Interleukin-6-Rezeptoranatagonist Tocilizumab (RoActemra®) ist in Kombination mit Methotrexat (MTX) seit Januar 2009 für die… (More)
Is this relevant?
2009
2009
In January 2009, tocilizumab (RoActemra; Chugai/Roche), a humanized monoclonal antibody that binds to the interleukin-6 receptor… (More)
Is this relevant?